C-Type Natriuretic Peptide Ameliorates Lipopolysaccharide-Induced Cardiac Dysfunction in Rats with Pulmonary Arterial Hypertension

Biomed Res Int. 2018 Dec 20:2018:2813025. doi: 10.1155/2018/2813025. eCollection 2018.

Abstract

Lipopolysaccharide induces rapid deterioration of cardiac function in rats with pulmonary arterial hypertension. It was desired to investigate if this cardiac dysfunction could be treated by C-type natriuretic peptide. Rat pulmonary arterial hypertension was induced by intraperitoneal injection of monocrotaline. Hemodynamics and cardiac function were measured by pressure-volume (P-V) catheter before and after the rats were treated with lipopolysaccharide and C-type natriuretic peptide. Cyclic guanosine 3',5'-monophosphate (cGMP) level was determined by enzyme-linked immunosorbent assay analysis. After the rats were injected with low-dose lipopolysaccharide, they experienced left ventricle systolic function deterioration. Administration of C-type natriuretic peptide improved hemodynamics and left ventricle systolic function. cGMP level was elevated after C-type natriuretic peptide treatment. C-type natriuretic peptide could ameliorate lipopolysaccharide-induced cardiac dysfunction and restore hemodynamic deterioration in rats with pulmonary arterial hypertension.

MeSH terms

  • Animals
  • Cyclic GMP / metabolism
  • Heart Diseases / chemically induced*
  • Heart Diseases / drug therapy*
  • Heart Diseases / metabolism
  • Heart Ventricles / drug effects*
  • Heart Ventricles / metabolism
  • Hemodynamics / drug effects
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / metabolism
  • Lipopolysaccharides / pharmacology*
  • Male
  • Monocrotaline / pharmacology
  • Natriuretic Peptide, C-Type / pharmacology*
  • Pulmonary Artery / drug effects*
  • Pulmonary Artery / metabolism
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Lipopolysaccharides
  • Natriuretic Peptide, C-Type
  • Monocrotaline
  • Cyclic GMP